Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.

Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class ...

Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. The loss of a shot at a milestone prompted OPM to lay off ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset ...

SURESNES, France - Servier, a global pharmaceutical group ... BDTX-4933 is designed to address the unmet medical needs of patients with RAF/RAS-mutant solid tumors. The ongoing Phase 1 clinical ...